Alkermes SWOT Analysis and Company Tech Intelligence Report 2018

Report Name: Alkermes Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation

Alkermes Report – Publisher: Research Cosmos

Price Scheme of the Report:

Single User License – USD 150

Team License – USD 175

Corporate License – USD 250

Alkermes – Business Description:

Alkermes is engaged in the research, development and commercialization of pharmaceutical products that are designed to address therapeutic areas. The company has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

The company’s key products include Risperdal Consta, Invega Sustenna, Xeplion, Invega Trinza, Trevicta, Ampyra, Fampyra, Bydureon, Vivitrol, and Aristada.

Alkermes’ Risperdal Consta is used for the treatment of schizophrenia and bipolar I disorder. Schizophrenia is a chronic, severe and disabling brain disorder; and bipolar I disorder is a brain disorder that causes unusual shifts in a person’s mood, energy and ability to function. Invega Sustena is used for the treatment of schizophrenia and schizoaffective disorder. Schizoaffective disorder is a condition in which a person experiences a combination of schizophrenia symptoms, such as delusions, hallucinations or other symptoms characteristic of schizophrenia, and mood disorder symptoms, such as mania or depression.

The company’s Xeplion, Invega Trinza and Trevicta are used for the treatment of schizophrenia. Ampyra and Fampyra are used for the treatment to improve walking in patients with multiple sclerosis, a chronic disease in which the immune system attacks and degrades the function of nerve fibers in the brain and spinal cord. Bydureon is used for the treatment of type 2 diabetes, a disease in which the body does not produce or properly use insulin.

Alkermes’ Vivitrol is a once-monthly injectable medication used for the treatment of alcohol dependence and the prevention of relapse to opioid dependence, following opioid detoxification. The company’s Aristada is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

The company’s subsidiaries include Alkermes Ireland Holdings Limited, Alkermes Science Four Limited, Alkermes Finance Ireland Limited, Alkermes Finance S.a r.l., Alkermes U.S. Holdings, and Daravita Limited.

Scope of the Report:

About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.

Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.

Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.

Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.

Key Questions Answered

What domain does Balfour Beatty plcoperate and what are key points about it?

What is the product/service portfolio of Atea ASA.?

How has Balfour Beatty plcperformed financially from 2013?

How does Balfour Beatty plcrank among its peers in terms of revenue and market share?

What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?

What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?

What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?

Reasons to buy

Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost

12 hour delivery time fulfilling your urgent requests as per your requirement

On-demand customization options that can completely cater to your needs by focusing the report on given specifics

For More Information, Get Sample of the report:Request Sample

Got Some Questions? Inquire Here:Inquire Before Buying

Get This Report:Purchase Now

For More Details, Contact Provider Directly:

Kevin Stewart
Sales Manager
Research Cosmos
kevin@researchcosmos.com
+1 888 709 8757

Be the first to comment

Leave a Reply